Business
Exercise of Warrants
ImmuPharma PLC announced the exercise of 500,000 warrants over new ordinary shares at 5p per share, resulting in a consideration of £25,000. These new ordinary shares, representing 0.10% of the company's enlarged issued share capital, have been allotted and will rank equally with existing shares. Application has been made for these shares to be admitted to trading on the AIM market, with admission anticipated around September 22, 2025. Following admission, the company's total issued share capital will consist of 502,723,932 ordinary shares with a nominal value of 1p each. Disclaimer*
About this update from Immupharma Plc
17 September 2025 ImmuPharma PLC ("ImmuPharma" or the "Company") Exercise of Options ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that the Company has received notice of exercise of 500,000 warrants over New Ordinary Shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £25,000. New Ordinary Shares and Admission The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company's existing issued ordinary shares. An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Monday 22 September 2025. The New Ordinary Shares represent 0.10% of the Company's enlarged issued share capital. Total Shares in Issue For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company's total issued share capital will consist of 502,723,932 Ordinary Shares with a nominal value of 1p each. This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR. Ends This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. For further information please contact: ImmuPharma PLC ( www.immupharma.co.uk ) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 20 3650 3650 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. For additional information about ImmuPharma please visit www.immupharma.co.uk . ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.